Author

E. E. Mulkearns-Hubert

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 5 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Research Focus:differential expression· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2

Frequent Co-Authors

J. Lathia· 4 shared D. J. Silver· 3 shared J. D. Lathia· 3 shared N. Hajdari· 3 shared S. Johnson· 3 shared C. G. Hubert· 2 shared K. Mitchell· 2 shared S. A. Sprowls· 2 shared

Activity by Year

2018-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

J. Lathia

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

miR-644a is a tumor cell-intrinsic mediator of sex bias in glioblastoma

E. S. Hong, S. Z. Wang, A. K. Ponti, N. Hajdari, J. Lee, E. E. Mulkearns-Hubert, J. Volovetz, K. E. Kay, J. Lathia, A. Dhawan

This study identifies miR-644a as a tumor cell-intrinsic mediator of sex bias in glioblastoma, showing it is more highly expressed in females and its target genes are linked to poorer survival.

bioRxiv · Mar 11, 2024Cancer Biology

Tumor cell-intrinsic HFE drives glioblastoma growth

K. M. Troike, D. J. Silver, P. K. Ghosh, E. E. Mulkearns-Hubert, C. G. Hubert, J. R. Connor, P. L. Fox, B. W. Kristensen, J. Lathia

This study shows that HFE promotes glioblastoma growth by regulating iron homeostasis and oxidative stress, with HFE loss inducing apoptosis and extending survival.

bioRxiv · Apr 13, 2022 · PreprintCancer Biology

VRK1 is a Paralog Synthetic Lethal Target in VRK2-methylated Glioblastoma

J. A. Shields, S. R. Meier, M. Bandi, M. Dam Ferdinez, J. L. Engel, E. E. Mulkearns-Hubert, N. Hajdari, K. Mitchell, W. Zhang, S.-c. Zhao, M. Zhang, R. Tjin Tham Sjin, E. Wilker, J. Lathia, J. Andersen, , N. Emmanuel

This study identifies VRK1 as a synthetic lethal target in VRK2-methylated glioblastoma by showing that VRK1 inhibition leads to tumor growth inhibition in xenograft models.

bioRxiv · Dec 30, 2021 · PreprintCancer Biology

WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma

K. Mitchell, S. Shakya, S. Arora, S. A. Sprowls, D. J. Silver, C. M. Goins, L. Wallace, G. Roversi, R. Schafer, K. Kay, T. E. Miller, A. Lauko, A. Kashyap, J. D. Kass, E. E. Mulkearns-Hubert, , J. D. Lathia

This study identifies WDR5 as an essential epigenetic regulator in therapy-resistant glioblastoma cancer stem cells and shows that WDR5 inhibitors disrupt CSC maintenance and tumor growth.

bioRxiv · Sep 20, 2021Cancer Biology

Targeting the Cx26/NANOG/Focal Adhesion Kinase Complex via Cell Penetrating Peptides in Triple Negative Breast Cancers

E. E. Mulkearns-Hubert, E. Esakov, S. Ben-Salem, R. Bharti, N. Hajdari, S. Johnson, A. Myers, I. N. Smith, S. Bandyopadhyay, C. Eng, E. Downs-Kelly, J. Lathia, O. Reizes

This study demonstrates that a cell-penetrating peptide targeting the Cx26/NANOG/FAK complex inhibits tumor growth and alters NANOG activity in triple-negative breast cancer.

bioRxiv · Sep 9, 2021 · PreprintCancer Biology

Preclinical modeling of surgery and steroid therapy for glioblastoma reveals changes in immunophenotype that are associated with tumor growth and outcome

B. Otvos, T. J. Alban, M. M. Grabowski, D. Bayik, E. E. Mulkearns-Hubert, T. Radivoyevitch, a. Rabljenovic, S. Johnson, C. Androjna, A. M. Mohammadi, G. Barnett, M. S. Ahluwalia, M. A. Vogelbaum, P. E. Fecci, J. D. Lathia

The paper develops a mouse model to study how surgery and steroids affect immune responses in glioblastoma, finding systemic lymphocyte reduction and correlations with tumor growth and patient outcomes.

bioRxiv · Aug 12, 2020Cancer Biology

Development of a Cx46 targeting strategy for cancer stem cells

E. E. Mulkearns-Hubert, L. A. Torre-Healy, D. J. Silver, J. T. Eurich, E. Serbinowski, M. Hitomi, J. Zhou, B. Przychodzen, R. Zhang, S. A. Sprowls, J. S. Hale, T. Alban, A. Berezovsky, B. A. Bell, P. R. Lockman, , J. D. Lathia

This study identifies clofazimine as a Cx46 inhibitor that targets glioblastoma cancer stem cells by disrupting gap junction communication, enhancing the efficacy of temozolomide.

bioRxiv · Mar 26, 2018Cancer Biology